Novavax (NVAX), European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Novavax (NVAX), European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

August 4, 2021 9:10 AM EDT

GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for an additional 100 million doses through 2023.

Novavax is working to complete its rolling submission for NVX-CoV2373 to the European... More